AUTHORS
Abhishek Maiti, MBBS, Jae H Park, MD2, Jing Chen, MD3, Mahiuddin Ahmed, PhD4, Sonia MS MS Sequeira, PhD5
AFFILIATIONS
1 MD Anderson, Houston, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Hackensack Meridian School of Medicine, Nutley, New Jersey, United States
4 VITRUVIAE, Nutley, New Jersey, United States
5 VITRUVIAE, Nutley, New Jersey, United States
ABSTRACT
Relapsed or refractory acute myeloid leukemia (R/R AML), high-risk myelodysplastic syndromes (HR-MDS), and diffuse large B-cell lymphoma (DLBCL) following chimeric antigen receptor T-cell therapy are diseases with significant unmet clinical need.
T cell engaging immunotherapies have shown promise for these cancers, but remain limited by heterogeneous antigen expression, antigen loss, and on-target off-tumor toxicity, leading to treatment resistance and disease relapse.
VTRU200 is a novel trispecific T-cell engager that targets aberrant glycans (Man9/Fuc) and phosphatidylserine (PS), which are chronically exposed on the surface of tumor cells, and engages CD3 on T-cells. These signatures are broadly expressed on malignant cells and cancer stem cells independent of genomic alterations. Dual targeting of glycan and lipid signatures is designed to improve the therapeutic index of VTRU200 compared to prior TCEs by enhancing antitumor activity, reducing susceptibility to antigen escape, and minimizing binding to normal tissues.
In preclinical studies, VTRU200 demonstrated potent and durable antitumor activity in PDX and CDX AML models, with activity observed at doses as low as 0.07 mg/kg and no treatment-related toxicity in mice at doses up to 5 mg/kg, the highest dose tested. No off-target binding was detected in normal human tissues or normal hematopoietic cell populations, and VTRU200 did not induce measurable cytokine release in human blood samples, in the absence of tumor. These findings provide a rationale for first-in-human clinical evaluation of VTRU200.
Study Design and Methods
This study will enroll adults with R/R AML, HR-MDS, or DLBCL following standard treatments. Pediatric patients with R/R AML will be enrolled in subsequent expansion cohorts. Eligible patients must have measurable disease, an ECOG performance status 0–2, and adequate organ function. This first-in-human, open-label, multicenter Phase 1/2 study will evaluate intravenous VTRU200 using an adaptive accelerated titration followed by BOIN dose escalation to determine the recommended Phase 2 dose (RP2D). Patients will receive weekly intravenous VTRU200 during cycles 1 and 2, with transition to Q2W or Q4W dosing beginning in cycle 3. Dose escalation will begin in adults with AML and HR-MDS, followed by DLBCL and adolescent AML after demonstration of acceptable adult safety, informed by real-time data analysis. Phase 2 expansion cohorts will further evaluate safety and preliminary antitumor efficacy, with adult R/R AML designated as the primary efficacy cohort. Primary Phase 1 endpoints include safety, tolerability, dose-limiting toxicities, pharmacokinetics, and the RP2D. Primary Phase 2 efficacy endpoints include complete remission (CR) and CR with partial hematologic recovery (CRh) in R/R AML, CR in HR-MDS, and CR in DLBCL. Secondary and exploratory endpoints include antitumor activity, target expression and clearance, immunogenicity, immune characterization, and circulating biomarkers.
DISCLOSURES
Abhishek Maiti, MBBS: Lin Biosciences - Research Funding; Hibercell Inc. - Research Funding; BioSight - Research Funding; Electra Therapeutics - Research Funding; Arce Therapeutics - Research Funding; Astex Pharmaceuticals - Research Funding; Indapta Therapeutics - Research Funding; Inspirna - Research Funding; Cero Therapeutics - Research Funding; Chimeric Therapeutics - Research Funding; IGM Biosciences - Research Funding; BMS - Research Funding; Takeda Pharmaceuticals - Research Funding; CytoMed Therapeutics - Research Funding; Sanofi Aventis - Research Funding; Cero Bio - Research Funding; Captor Therapeutics - Consultancy (Includes expert testimony); Galecto - Consultancy (Includes expert testimony); Ferring Ventures - Consultancy (Includes expert testimony); Electra Therapeutics - Consultancy (Includes expert testimony); Ingenium Therapeutics - Consultancy (Includes expert testimony); Orum Therapeutics - Consultancy (Includes expert testimony)